Company news

BioAtla, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

March 18, 2024

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 6, 2024

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

December 12, 2023

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

December 5, 2023

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

December 4, 2023

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

November 29, 2023

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

November 27, 2023

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

November 6, 2023

BioAtla to Participate in the Jefferies London Healthcare Conference

November 5, 2023

BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

October 11, 2023

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

October 9, 2023

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

BioAtla to Participate in Upcoming Investor Conferences in August

August 2, 2023

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

July 31, 2023

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

July 24, 2023

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

June 25, 2023

BioAtla to Participate in the Jefferies Healthcare Conference

May 30, 2023

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 10, 2023

BioAtla to Participate in the JMP Securities Life Sciences Conference

May 7, 2023

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

May 3, 2023

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

March 22, 2023

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

March 15, 2023

BioAtla Announces Change in Executive Leadership

February 26, 2023

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

February 22, 2023

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

January 9, 2023

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

November 3, 2022

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

November 2, 2022

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

October 26, 2022

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

August 8, 2022

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

August 2, 2022

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

August 1, 2022

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

May 31, 2022

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

May 3, 2022

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

April 7, 2022

BioAtla announces fourth quarter and full year 2021 financial results

February 28, 2022

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

January 9, 2022

BioAtla appoints edward l. Williams to board of directors

December 20, 2021

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update

November 14, 2021

BioAtla Announces Private Placement of 2.7 Million Shares

September 28, 2021

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

August 12, 2021

BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update

May 11, 2021

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

March 8, 2021

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

December 17, 2020

BioAtla Announces Pricing of Initial Public Offering

December 14, 2020

← Newer news releases

Calls

The 5 newest of 15 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.